What is the recommended dosing schedule for iron sucrose 200 mg intravenously administered weekly for five doses?

Iron Sucrose 200 mg IV Weekly for Five Doses

For adult patients with iron deficiency anemia, administer iron sucrose 200 mg intravenously once weekly for five consecutive weeks, either as a slow IV push over 2–5 minutes or as an infusion diluted in 100 mL of 0.9% NaCl over 15–30 minutes, delivering a total cumulative dose of 1000 mg. 1

FDA-Approved Dosing Protocol

The FDA label for Venofer (iron sucrose) provides explicit guidance for this regimen:

• Dose per administration: 200 mg elemental iron 1
• Frequency: Five doses administered on separate occasions over a 14-day period 1
• Administration methods:
  • Slow IV push: 200 mg undiluted over 2–5 minutes 1
  • IV infusion: 200 mg diluted in maximum 100 mL of 0.9% NaCl over 15 minutes 1
• Total cumulative dose: 1000 mg over the treatment course 1

This dosing schedule is specifically FDA-approved for non-dialysis dependent chronic kidney disease (NDD-CKD) patients but is widely applied across multiple clinical contexts 1.

Guideline-Based Recommendations

Maximum Dose Considerations

The maximum single dose of iron sucrose should not exceed 200 mg per injection to minimize dose-related anaphylactoid reactions. 2

• Individual doses above 300 mg are not recommended by regulatory authorities 3, 2
• The maximum weekly cumulative dose is 500 mg 2
• Doses of 400–500 mg are associated with markedly higher rates of adverse reactions 2

Alternative Dosing Schedules

While the five-dose weekly regimen is standard, guidelines acknowledge flexibility:

• Every 2–3 weeks: The NCCN guidelines support 200 mg IV every 2–3 weeks as an alternative schedule for cancer patients 3
• Twice weekly: For more rapid repletion, 200 mg can be given twice weekly 4
• Total treatment course: Typically requires 4–7 visits to achieve full iron repletion with iron sucrose 3, 2

Administration Technique and Safety

Pre-Administration Assessment

Test doses are NOT required for iron sucrose, unlike iron dextran. 3, 2, 1

However, test doses are strongly recommended for patients with:

• History of sensitivities to other IV iron preparations 3, 2
• Multiple drug allergies 3, 2
• Severe asthma, eczema, or mastocytosis 2

Absolute contraindication: Active bacteremia or bloodstream infection 3, 2

Infusion Monitoring Protocol

• Start slowly: Begin infusion at a reduced rate for the first 5 minutes to monitor for reactions 2
• Observation period: Monitor patients for at least 30 minutes after infusion completion 2
• Resuscitation readiness: Ensure immediate availability of trained personnel, IV epinephrine, and resuscitation equipment 2
• Vital signs: Monitor during and after infusion 3, 2

Management of Infusion Reactions

Most reactions are complement activation-related pseudo-allergy (CARPA), not true IgE-mediated anaphylaxis 2:

• For mild reactions: Stop infusion, switch to hydration fluid, monitor for 15 minutes, then rechallenge at slower rate 2
• For persistent symptoms: Consider IV corticosteroid (hydrocortisone) 2
• Avoid diphenhydramine: Its side effects can mimic worsening reactions 3

Expected Outcomes and Monitoring

Efficacy Endpoints

Hemoglobin typically increases by 1–2 g/dL within 4–8 weeks of completing the five-dose regimen. 5

• Mean hemoglobin increase: 1.7 g/dL observed in clinical trials 1
• Ferritin increase: Mean rise of 288–434 ng/mL 1, 6
• Transferrin saturation increase: 8–14% 1, 6
• Clinical response rate: 44–54% of patients achieve hemoglobin >11 g/dL 1, 6

Post-Treatment Monitoring

Recheck hemoglobin and iron parameters 4–8 weeks after the final dose. 5, 7

• Do not measure iron parameters within 4 weeks of IV iron administration, as ferritin levels are falsely elevated 5
• Target ferritin: ≥100 ng/mL 3, 5
• Target transferrin saturation: ≥20% 3, 5
• For ongoing monitoring: Check iron status every 3 months if on regular therapy 3, 5

Adverse Effects Profile

Iron sucrose has a well-established safety profile with approximately 0.5% incidence of hypersensitivity-type reactions, significantly lower than iron dextran. 2

Common Adverse Effects (1–2% incidence):

• Hypotension or hypertension 3, 2
• Nausea, vomiting, diarrhea 3, 2
• Headache, dizziness 3, 2
• Flushing, pruritus 3, 2
• Arthralgia, myalgia 2

Metabolic Complications

Hypophosphatemia occurs in only 1% of iron sucrose patients, compared to 58% with ferric carboxymaltose. 3, 2

• Monitor serum phosphate in patients receiving long-term or multiple high-dose infusions 3, 2
• Iron sucrose has the lowest hypophosphatemia risk among modern IV iron formulations 3, 2

Clinical Context and Comparisons

When to Choose Iron Sucrose

Iron sucrose is particularly appropriate for:

• Patients with chronic kidney disease (dialysis or non-dialysis dependent) 1
• Cancer patients with chemotherapy-induced anemia 3, 7
• Inflammatory bowel disease with impaired oral absorption 3, 8
• Post-bariatric surgery patients 3
• Patients intolerant to oral iron 6, 8

Practical Considerations

Iron sucrose requires multiple visits (typically 5–7) compared to newer formulations that can deliver 1000 mg in 1–2 infusions. 3, 2

• Cost: Iron sucrose costs approximately $442 for 1000 mg total dose 3
• Convenience: Newer agents (ferric carboxymaltose, ferric derisomaltose) offer single-dose repletion but cost $3470–$3896 3
• Safety trade-off: Iron sucrose has lower hypophosphatemia risk than ferric carboxymaltose 3, 2

Pediatric Dosing (≥2 years)

For children, the dosing differs from adults:

• Maintenance dose: 0.5 mg/kg (maximum 100 mg) every 2 weeks for hemodialysis patients 1
• Non-dialysis/peritoneal dialysis: 0.5 mg/kg (maximum 100 mg) every 4 weeks 1
• The 200 mg × 5 dose regimen is NOT established for pediatric iron replacement 1

Key Clinical Pitfalls to Avoid

• Do not exceed 200 mg per single dose to minimize anaphylactoid reactions 2
• Do not administer during active bacteremia, though chronic infection alone is not an absolute contraindication 3, 2
• Do not check iron parameters within 4 weeks of the last dose, as ferritin will be falsely elevated 5
• Do not assume test doses are required—iron sucrose does not mandate test dosing unlike iron dextran 3, 1
• Do not use diphenhydramine for infusion reactions—it can worsen the clinical picture 3